Description: Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acidic and allied products comprising sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India.
Home Page: www.aartipharmalabs.com
204, Udyog Kshetra
Mumbai,
400 080
India
Phone:
91 22 6943 6100
Officers
| Name | Title |
|---|---|
| Ms. Hetal Gogri Gala | Vice Chairperson & MD |
| Mr. Narendra Jagannath Salvi | MD & Director |
| Mr. Piyush P. Lakhani | Chief Financial Officer |
| Mr. G.M. Naidu | Head of Operations & Manufacturing, CDMO & CMO |
| Mr. Sudhakar Shetty | Senior General Manager of HR & Admin |
| Dr. B. S. Patravale | President of R&D |
| Mr. Jasmin Mehta | Head of Business Development & Direct Procurement |
| Mr. Sachin Patil | Head of API Export Regulated and R&D Management |
Exchange: BSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 24.9603 |
| Price-to-Book MRQ: | 3.0889 |
| Price-to-Sales TTM: | 2.8954 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 2095 |